Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 14,322 Shares of Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total transaction of $103,404.84. Following the completion of the transaction, the chief technology officer now directly owns 96,790 shares in the company, valued at approximately $698,823.80. The trade was a 12.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Seshu Tyagarajan also recently made the following trade(s):

• On Friday, November 29th, Seshu Tyagarajan sold 20,392 shares of Candel Therapeutics stock. The shares were sold at an average price of $4.56, for a total transaction of $92,987.52.

Candel Therapeutics Stock Performance

Shares of NASDAQ CADL opened at $6.66 on Friday. Candel Therapeutics, Inc. has a fifty-two week low of $1.16 and a fifty-two week high of $14.60. The company has a market cap of $216.32 million, a PE ratio of -3.85 and a beta of -1.20. The business has a 50-day simple moving average of $6.61 and a two-hundred day simple moving average of $6.28.

Institutional Trading of Candel Therapeutics

A number of institutional investors have recently bought and sold shares of CADL. Point72 DIFC Ltd acquired a new position in Candel Therapeutics during the 2nd quarter valued at approximately $31,000. FMR LLC acquired a new position in shares of Candel Therapeutics in the 3rd quarter valued at $46,000. MetLife Investment Management LLC purchased a new position in Candel Therapeutics in the 3rd quarter worth $87,000. Atom Investors LP acquired a new stake in Candel Therapeutics during the 3rd quarter worth about $103,000. Finally, State Street Corp grew its stake in Candel Therapeutics by 4.1% during the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after purchasing an additional 19,207 shares during the last quarter. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $19.00 price objective (up previously from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.